Although promotion of lymphangiogenesis by VEGF‐C seems a promising strategy for colitis alleviation in mouse models (D'Alessio et al, 2014), there is still no proven benefit for IBD patients of targeting angiogenesis, whether indirectly (inhibiting the immune response) or directly (inhibiting VEGF or other angiogenic molecules as TNFα) (Chidlow et al, 2006; Eder et al, 2015). The gene discussed is VEGFA; the disease is inflammatory bowel disease.